Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology
+$0.14 today
- Market cap
- $3.42B
- Beta
- -0.16
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.36
Volume 1.51M
Average 1.21M
AMLX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$45.46M, compared with -$34.27M a year earlier. Trailing-twelve-month EBITDA was -$160.97M.
Context
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$142.35M (+1.3%) for the fiscal year ending Dec 2026, a slowdown from the +50.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$45.46M-4.8% QoQ
- Last fiscal yearDec 2025
- -$144.16M+50.5% YoY
- LTMSep 2026
- -$160.97M-7.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -32.7% | -47.4% | -14.7 pp |
| 1 year | +50.5% | +1.3% | -49.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (144.16M) USD
- Year-over-year change
- +50.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (144.16M) | +50.5% |
| FY2024 | 2024-12-31 | (290.98M) | -625.4% |
| FY2023 | 2023-12-31 | 55.39M | +128.1% |
| FY2022 | 2022-12-31 | (197.11M) | -124.3% |
| FY2021 | 2021-12-31 | (87.88M) | — |
EBITDA vs competitors
How AMLX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.8% is the 4th highest of 10, against a peer median of -29.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$29.2M USD | -21.6% | — | 21792.5% | |
| LTM Dec 2025 | -$38.87M USD | +24.6% | — | — | |
| LTM Jun 2026 | -$42.73M USD | -201.1% | — | — | |
| LTM Mar 2026 | -CHF 64.45M CHF | -29.6% | — | 1740.8% | |
| LTM Mar 2026 | -$74.72M USD | +35.0% | — | 129.0% | |
| LTM Mar 2026 | -$78.03M USD | -325.2% | — | — | |
| LTM Sep 2026 | -$160.97M USD | -7.8% | — | — | |
| LTM Sep 2026 | -$359.29M USD | -31.7% | — | — | |
| LTM Sep 2026 | -$473.54M USD | -208.3% | — | 49.3% | |
| LTM Jun 2026 | -$498.21M USD | -6.5% | — | 13823.7% | |
| Peer median (excluding AMLX) | — | -29.6% | — | 1740.8% | |
Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 22.23M | 380.79M | 87.37M | 0 |
| Cost of Revenue | 0 | 2.99M | 25.44M | 42.16M | 525K |
| Gross Profit | 0 | 19.24M | 355.35M | 45.22M | (525K) |
| Gross Margin | — | 86.5% | 93.3% | 51.8% | — |
| Research & Development | 44.04M | 93.45M | 128.19M | 104.08M | 90.4M |
| Selling, General & Admin | 38.93M | 127.13M | 188.36M | 114.33M | 62.89M |
| Operating Expenses | 82.69M | 220.58M | 316.54M | 359.95M | 152.77M |
| Depreciation & Amortization | 52K | 487K | 1.09M | 904K | 525K |
| EBITDA | (87.88M) | (197.11M) | 55.39M | (290.98M) | (144.16M) |
| EBITDA Margin | — | -886.7% | 14.5% | -333.0% | — |
| Operating Income | (82.69M) | (201.34M) | 38.8M | (314.73M) | (153.29M) |
| Operating Margin | — | -905.7% | 10.2% | -360.2% | — |
| Interest Income | 36K | 4.29M | 16.16M | 13.81M | 9.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (5.24M) | 3.74M | 15.5M | 12.6M | 8.6M |
| Income Before Tax | (87.93M) | (197.6M) | 54.3M | (302.14M) | (144.69M) |
| Pre-Tax Margin | — | -888.9% | 14.3% | -345.8% | — |
| Income Tax Expense | 0 | 774K | 5.03M | (393K) | 46K |
| Net Income | (87.93M) | (198.38M) | 49.27M | (301.74M) | (144.74M) |
| Net Margin | — | -892.4% | 12.9% | -345.4% | — |
| EPS (Basic) | (1.52) | (2.98) | 0.73 | (4.43) | (1.53) |
| EPS (Diluted) | (1.52) | (2.98) | 0.70 | (4.43) | (1.53) |
| Weighted Avg Shares | 57.86M | 66.51M | 67.23M | 68.14M | 94.57M |
| Weighted Avg Shares (Diluted) | 57.86M | 66.51M | 69.99M | 68.14M | 94.57M |
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
Intrinsic Alpha fair value
Locked
Current Price
$26.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.